Endpoints Shorts: Dr. Nadia Sethi on AL-S Pharma's AP-101

Endpoints

Jul 24, 2023•6 min

--:--

Listen in podcast apps:

Apple Podcasts

Spotify

Download

Listen to this episode in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute.

In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less.

Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk about AL-S Pharma’s phase 2 trial for AP-101.

That there are currently no treatments to stop or reverse ALS but the ALS Therapy Development Institute is working to change that. To learn more about ALS TDI and our research to end ALS, visit als.net.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

For the best experience, listen in Metacast app for iOS or Android